Catalog No.
DHC12507
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-nd
Clonality
Monoclonal
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Concentration
1.44 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05067
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AAB-001, CAS: 648895-38-9
Clone ID
Bapineuzumab
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease, PMID: 24450891
Bapineuzumab, PMID: 20497044
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis, PMID: 22305802
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?, PMID: 23574434
Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease, PMID: 21091109
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease, PMID: 29920980
Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials, PMID: 28376794
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies, PMID: 32989305
Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study, PMID: 30129411
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies, PMID: 27334799
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials, PMID: 27176461
Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab, PMID: 21592055
Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease, PMID: 26639957
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β, PMID: 29686315
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab, PMID: 29429971
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study, PMID: 29914022
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab, PMID: 27163805
Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis, PMID: 29296624
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation, PMID: 23416764
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies, PMID: 30412493
Bapineuzumab in Alzheimer's disease: where now?, PMID: 20129159
Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease, PMID: 26044070
Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy, PMID: 23555764
Bapineuzumab, an investigational agent for Alzheimer's disease, PMID: 23599675
Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient, PMID: 21263194
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease, PMID: 27589523
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials, PMID: 29854934
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study, PMID: 20189881
A single ascending dose study of bapineuzumab in patients with Alzheimer disease, PMID: 20505438
APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics, PMID: 19923549
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis, PMID: 33046560
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials, PMID: 26208959
Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis, PMID: 25669746
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease, PMID: 22473769
Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease, PMID: 25187399
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab, PMID: 29854935
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716688
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24724181
Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients, PMID: 28269765
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, PMID: 19923550
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models, PMID: 26467270
[Immunotherapy for Alzheimer's disease], PMID: 26815584
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716689
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716687
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies, PMID: 22339463
Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β, PMID: 24598931
Disease modifying drugs targeting β-amyloid, PMID: 22815077
Tau aggregates as immunotherapeutic targets, PMID: 23277060
For research use only. Not for human or drug use.
